实用肝脏病杂志 ›› 2026, Vol. 29 ›› Issue (1): 65-68.doi: 10.3969/j.issn.1672-5069.2026.01.017

• 非酒精性脂肪性肝病 • 上一篇    下一篇

五灵胶囊治疗代谢相关脂肪性肝炎患者临床疗效研究*

臧文军, 王荔, 张霞   

  1. 116021 辽宁省大连市第五人民医院内分泌科(臧文军,王荔);大连医科大学附属第二医院内分泌1科(张霞)
  • 收稿日期:2025-06-20 出版日期:2026-01-10 发布日期:2026-02-04
  • 通讯作者: 王荔,E-mail:wangli1982823@sohu.com
  • 作者简介:臧文军,女,58岁,大学本科,主任医师。E-mail:r91e86@163.com
  • 基金资助:
    *辽宁省大连市科技局医学科学研究计划项目(编号:1911036)

Clinical observation of Wuling capsule in the treatment of patients with metabolic associated steatohepatitis

Zang Wenjun, Wang Li, Zhang Xia   

  1. Department of Endocrinology, Fifth People's Hospital,Dalian 116021,Liaoning Province, China
  • Received:2025-06-20 Online:2026-01-10 Published:2026-02-04

摘要: 目的 探讨应用五灵胶囊治疗代谢相关脂肪性肝炎(MASH)患者的临床疗效。方法 2018年1月~2023年12月我院收治的117例MASH患者,被随机分为对照组58例和观察组59例,分别给予饮食控制、运动和降脂的基础上联合多烯磷脂酰胆碱胶囊治疗或在此基础上给予五灵胶囊治疗6个月。采用ELISA法检测血清透明质酸(HA)、层粘蛋白(LN)、Ⅲ型前胶原(PCⅢ)和Ⅳ型胶原(IV-C)及白细胞介素-1β(IL-1β)、IL-6、IL-18、IL-37和肿瘤坏死因子(TNF-α)。结果 在治疗6个月末, 观察组血清ALT、AST和GGT水平分别为(39.7±7.2)U/L、(36.3±8.6)U/L和(63.6±5.8)U/L,均显著低于对照组【分别为(60.5±8.9)U/L、(56.7±9.2)U/L和(72.5±9.2)U/L,P<0.05】;血清HA、PCⅢ和Ⅳ-C水平分别为(166.3±30.8)μg/L、(106.1±34.2)μg/L和(108.2±18.4)μg/L,均显著低于对照组【分别为(189.6±36.3)μg/L、(147.4±36.4)μg/L和(126.5±20.7)μg/L,P<0.05】;血清IL-1β、IL-6、IL-18和TNF-α水平分别为(11.8±2.4)pg/ml、(18.2±3.1)mg/L、(139.2±34.7)pg/ml和(3.6±1.1)ng/L,均显著低于对照组【分别为(16.4±2.7)pg/ml、(27.4±3.3)mg/L、(206.5±52.3)pg/ml和(6.3±1.2)ng/L,P<0.05】。结论 在综合干预的基础上,应用五灵胶囊治疗MASH患者短期疗效确切,可有效改善肝功能,降低肝纤维化和炎症指标水平,值得深入研究。

关键词: 代谢相关脂肪性肝炎, 五灵胶囊, 肝纤维化指标, 细胞因子, 治疗

Abstract: Objective The aim of this study was to investigate the clinical efficacy of Wuling capsule, a herbal compound, in the treatment of patients with metabolic associated steatohepatitis (MASH). Methods 117 patients with MASH were enrolled in our hospital between January 2018 and December 2023, and were randomly assigned to receive oral polyene phosphatidylcholine capsule in 58 cases in control or receive Wuling capsule and polyene phosphatidylcholine capsule combination in another 59 cases in observation for six months. All patients were carefully supervised with food intake and exercise, and hypolipidemic therapy when necessary. Serum hyaluronic acid (HA), laminin (LN), type Ⅲ procollagen N-terminal peptide (PCⅢ) and type Ⅳ collage (IV-C), and serum interleukin-1β(IL-1β), IL-6, IL-18, IL-37 and tumor necrosis factor-α(TNF-α) levels were detected by ELISA. Results By the end of 6 month treatment, serum alanine aminotransferase, aspartate aminotransferase and gamma-glutamyl transferase levels in the observation group were(39.7±7.2)U/L, (36.3±8.6)U/L and (63.6±5.8)U/L, all significantly lower than [(60.5±8.9)U/L, (56.7±9.2)U/L and (72.5±9.2)U/L, respectively, P<0.05] in the control; serum HA, PCⅢ and Ⅳ-C levels were (166.3±30.8)μg/L, (106.1±34.2)μg/L and (108.2±18.4)μg/L, all much lower than [(189.6±36.3)μg/L, (147.4±36.4)μg/L and (126.5±20.7)μg/L, respectively, P<0.05] in the control; serum IL-1β, IL-6, IL-18 and TNF-α levels were (11.8±2.4)pg/ml, (18.2±3.1)mg/L, (139.2±34.7)pg/ml and (3.6±1.1)ng/L, all much lower than [(16.4±2.7)pg/ml, (27.4±3.3)mg/L, (206.5±52.3)pg/ml and (6.3±1.2)ng/L, respectively, P<0.05] in the control group. Conclusion Wuling capsule has exact efficacy in the treatment of patients with MASH, which effectively improve liver function tests, and relieve liver fibrosis and cytokine reactions.

Key words: Metabolic associated steatohepatitis, Wuling capsule, a herbal medicine, Liver fibrosis, Cytokines, Therapy